• Recent research highlighted that the global antibody discovery market is expected to reach about US$35.35 billion by 2035, driven by advances in engineering technologies, automation, and artificial intelligence, with Twist Bioscience identified as one of the key industry participants.
• This positions Twist Bioscience at the center of a rapidly evolving field where AI-enabled, high-throughput discovery platforms are becoming increasingly important for precision therapies.
• We’ll now examine how Twist Bioscience’s role in AI-enabled antibody discovery shapes its broader investment narrative for long-term oriented investors.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 32 best rare earth metal stocks of the very few that mine this essential strategic resource.

What Is Twist Bioscience's Investment Narrative?

To own Twist Bioscience, you need to believe that its DNA synthesis and antibody discovery platform can translate scientific relevance into a path toward lower losses over time, even if profitability is still some way off. The recent research calling out Twist as a key player in a US$35.35 billion antibody discovery market reinforces the long-term story around its AI-enabled discovery engine, but it does not suddenly change the near-term catalysts, which still hinge on upcoming Q1 2026 results, revenue guidance and cash burn trends. With the share price having run up recently despite continued losses and insider selling, the bigger question is whether expectations around AI-driven antibody discovery are racing ahead of the company’s current financial reality.

However, investors also need to weigh one specific governance concern that could become more important over time. In light of our recent valuation report, it seems possible that Twist Bioscience is trading beyond its estimated value.

Exploring Other Perspectives

Three Simply Wall St Community fair value estimates cluster between US$35.47 and US$42, showing how individual views can spread across a relatively tight band. Against that, you still have the same core tension from earlier: high hopes around AI-enabled antibody discovery on one side, and a business that remains unprofitable with executive pay already at a premium on the other. Together, these perspectives highlight why it can be useful to compare several viewpoints before forming your own stance on Twist Bioscience.

Explore 3 other fair value estimates on Twist Bioscience - why the stock might be worth 17% less than the current price!

Build Your Own Twist Bioscience Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Twist Bioscience research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision.
• Our free Twist Bioscience research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Twist Bioscience's overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• This technology could replace computers: discover 23 stocks that are working to make quantum computing a reality.
• Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave.
• Uncover the next big thing with financially sound penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.